Molecular pharmaceutics
Preclinical and Initial Clinical Evaluation of 68Ga/177Lu-Labeled Heterodimer Agents Targeting Somatostatin Receptors and Integrin αVβ3.
Linlin Li, Xingtong Peng, Jialin Xiang, Chenhao Jia, Rongxi Wang, Wenbin Jin, Jiarou Wang, Yanwei Wang, Yaping Luo, Yuanyuan Jiang, Zhaohui Zhu
Published: 202510.1021/acs.molpharmaceut.5c01238
Abstract
Highly overexpressed somatostatin receptors (SSTRs), especially SSTR2, are frequently characterized in neuroendocrine tumors (NETs) and serve as a target for imaging and peptide receptor radionuclide therapy (PRRT). However, the SSTR2 expression decr…
Preview only. Read the full abstract at the source